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An Evaluation of the Prevalence of
Vancomycin-Resistant Enterococci (VRE) and
Methicillin-Resistant Staphylococcus aureus
(MRSA) in Hospital Food
Methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococci (VRE) are associated with sig-
niﬁcant patient morbidity and mortality.1 MRSA and VRE have
been found in retail foods, primarily animal products,2–6 but the
role of hospital food in MRSA and VRE transmission in health-
care facilities is unknown. The purpose of this study was to
determine the prevalence of MRSA and VRE in hospital food,
with an emphasis on foods consumed by hospital patients.
methods
This prospective cohort study was conducted at Barnes-Jewish
Hospital, a 1,250 bed tertiary care center in St Louis, Missouri,
from May 2011 through July 2012 in conjunction with a study
of Clostridium difﬁcile in hospital food.7 Our methods were
described previously.7,8 Brieﬂy, patients onmedical and surgical
wards collected food samples from their meals in sterile speci-
men cups (1 cup per meal; ≥1 food item per cup) to ensure that
the foods sampled were those consumed by patients. Food
specimens were frozen at −30°C. Prior to culture, specimens
were thawed, combined with 10 mL sterile water, and homo-
genized for 1 minute. A 1 mL volume of food homogenate was
added to TSB broth with 6.5% NaCl; then the mixture was
incubated overnight at 35°C. The broth was subcultured on
sheep blood agar (Hardy Diagnostics, SantaMaria, CA), Spectra
MRSA (Remel Diagnostics, Lenexa, KS), and chromID VRE
(bioMèrieux,Marcy-l'Étoile, France). The Vitek matrix-assisted
laser desorption/ionization time-of-ﬂight mass spectroscopy
(MALDI-TOFMS, bioMèrieux, Marcy-l'Étoile, France)method
was utilized to identify S. aureus or Enterococcus spp. Suscepti-
bility testing was performed using Kirby Bauer disk diffusion in
accordance with CLSI standards,9 and SCCmec typing was
performed.10
Data were collected from patient interviews, chart review, and
medical informatics queries, including MRSA and VRE clinical
laboratory results from 1 year before enrollment to 1 year after
enrollment. Descriptive data analyses were performed using
SPSS version 21 software (IBM, Armonk, NY). TheWashington
University Institutional Review Board approved the study.
results
In total, 149 patients were enrolled in the study and 910
food specimens were collected (median, 5 specimens per
patient; range, 1–24 specimens). The median patient age
was 55 years (range, 23–90 years); 80 patients (54%) were
female. 8 patients (5%) had clinical cultures (infection and/or
surveillance) positive for MRSA, and 7 patients (5%) had
clinical cultures positive for VRE, in the year before enrollment.
Overall, 1 or more food specimens from 17 patients (11%)
were positive for MRSA, and 1 or more food specimens from
17 patients (11%) were positive for VRE. MRSA was cultured
from 29 specimens (3.2%), and VRE was cultured from 22
specimens (2.4%); more than 1 positive specimen was col-
lected from some patients. Of the 29 MRSA-positive isolates,
9 (31%) were SCCmec II, 2 (7%) were SCCmec III, and 18
(62%) were SCCmec IV. Notably, 7 SCCmec IV isolates came
from a single patient (ie, 39% of SCCmec IV isolates). MRSA
and VRE were cultured from every food category except nuts
(Table 1). VRE was recovered from 5% of dairy or egg speci-
mens and MRSA was recovered from 5% of bread or grain
specimens and “other” specimens; for all other foods, the
culture positivity rate was <5%.
Only 4 patients (3%) had a clinical culture positive for
MRSA or VRE after having positive food without a previous
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clinical history of MRSA or VRE. MRSA was isolated from the
urine of patient A 28 days after the positive food specimen
(SCCmec IV) was collected. Patient B had 2 positive MRSA
surveillance screens, 48 and 50 days after the positive food
specimens were collected. MRSA was cultured from food
specimens collected by this patient on 5 separate days, and 7 of
the SCCmec IV isolates were obtained from specimens col-
lected by this patient. Enterococcus faecalis was cultured from
food collected by patient C 23 days before this patient had a
positive VRE surveillance screen. Between the food and screen
dates, patient C had 2 urine specimens positive for Enter-
ococcus (1 vancomycin susceptible, the other unknown) and
1 blood culture positive for E. faecalis (vancomycin susceptible).
Finally, 2 food specimens, positive for MRSA and E. faecalis,
were collected by patient D on 2 separate days, and this patient
had a positive VRE surveillance screen more than 3 months after
the positive food specimens were collected.
discussion
To the best of our knowledge, ours is the ﬁrst study to evaluate
the presence of MRSA and VRE in the food of hospitalized
patients. We previously found that food is unlikely to be a
signiﬁcant source of C. difﬁcile acquisition for hospitalized
patients.7 The prevalence of MRSA and VRE found in food in
the current study (3.2% and 2.4%, respectively) was higher
than the prevalence of C. difﬁcile (0.2%), but the overall con-
tamination rate was still low.
While this study was not designed to determine conclusively
whether patients acquired MRSA or VRE from their hospital
food, our results suggest that acquisition via food may be rare.
Additionally, patients enrolled in this study collected their own
food specimens; thus, the patients themselves may have been the
source of the contamination. Of the 4 patients with positive
MRSA or VRE clinical cultures after a positive food culture and
no prior clinical history of MRSA or VRE, 2 patients had MRSA
or VRE cultured from food specimens on more than 1 day.
Because the overall food contamination rate was low, this
pattern suggests patient contamination. Thus, prior clinical
history or possible self-contamination may eliminate the
possibility of food acquisition in all but 2 patients (1%).
While MRSA and VRE have been documented in retail food
previously, the comparability of results prior to our study
cannot be determined.2,3,5,6 The effect of food preparation on
the bacterial burden in hospital food is unknown. Despite
these limitations, our study indicates that MRSA and VRE
can be present in the food of hospitalized patients, and the
implications of this ﬁnding warrant additional study.
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table 1. Food Specimens Positive for Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant
Enterococci (VRE), by Food Typea
Food Item
No. of Samples
(N= 910)b
MRSA Positive
(N [%])c
VRE Positive
(N [%])c
Meat 308 7 (2) 9 (3)
Poultry 142 2 (1) 2 (1)
Fruit 179 2 (1) 2 (1)
Vegetable 455 14 (3) 5 (1)
Nuts 1 0 0
Dairy/eggs 210 7 (3) 11 (5)
Bread/grains 376 19 (5) 12 (3)
Other 200 9 (5) 3 (2)
Other (list) Veggie burger, sauce, pudding,
jelly, gravy (2), ﬁsh, cake (2)
Gravy (2), ﬁsh
aN= 149 patients; 910 food specimens.
bMore than 1 food item could be included in a sample.
cPercentages are number of positive specimens per total food items of that type.
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Placing Venous Catheters in the Home:
Pilot Data from the Mobile VAD Program
Patients requiring vascular access devices (VADs) for home
infusion therapy typically receive them as inpatients prior to
discharge home. However, for years many otherwise-stable
outpatients requiring VADs have avoided hospitalizations
altogether by having the VADs placed in ambulatory health-
care settings.1 In the novel Johns Hopkins Home Care Group
Mobile VAD Program, VAD placement is even removed from
ambulatory healthcare facilities such as clinics: trained nurses
place VADs in patient homes. The program allows the entire
home infusion therapy process (VAD placement, patient and
caregiver training, delivery of supplies, infusion therapy, and
assessment by home care nurses) to take place in the home,
outside healthcare settings. We present preliminary outcomes
from a prospective cohort of patients in the program.
methods
Starting in December 2015, outpatients1 requiring VADs but
not needing hospitalization were referred to the Mobile VAD
program. Telephone screenings ensured patients had a loca-
tion in the home appropriate for VAD placement (ie, with a
clean bed and a clean accessible sink, and where trafﬁc from
other household residents and pets can be avoided). A trained
nurse placed the VAD (peripherally inserted central catheter
[PICC] or midline catheter), using electrocardiogram (EKG)-
based technology to conﬁrm placement (Bard Site Rite 8
Ultrasound System, Bard Access Systems, Salt Lake City, UT).
Patients could then be followed by any home infusion agency
for medications, infusions, and supplies, and by any home
nursing agency for training and support in VAD care.
We expanded a previously described prospective cohort of
home infusion therapy patients2 to includeMobile VAD patients.
Eligible patients (>18 years of age, with a PICC or midline
catheter placed in the home through the Mobile VAD program
December 2015 through April 2017 for home infusion therapy)
consented to a telephone survey and chart abstraction 2 weeks
after VAD placement. Patients were ineligible if they were in
hospice care, did not speak English, or could not verbally consent.
Consenting patients completed a 10-minute telephone survey
focusing on VAD complications.2 The electronic health record
(EHR) was abstracted for demographic and clinical information
through 1 month after VAD removal. VAD days were calculated
as the number of days betweenVADplacement and removal. The
Charlson Comorbidity Index was calculated.3
The primary outcome was any VAD complication per 1,000
home VAD days and included any of the following:
central-line–associated bloodstream infection (CLABSI),
catheter-associated venous thromboembolism (CA-VTE),
bloodstream infection (BSI), or VAD occlusion, dislodgement,
accidental removal, kinking, coiling, breaking, phlebitis, or
linking. CA-VTE was deﬁned as a venous thromboembolism
(VTE) on imaging in any location, as PICCsmay be risk factors
for upper and lower VTEs.4 CLABSI were deﬁned based on
Association for Professionals in Infection Control (APIC) cri-
teria for CLABSI in home infusion5 (adapted from National
Healthcare Surveillance Network [NHSN] CLABSI deﬁnitions).6
Bloodstream infections were deﬁned as at least 2 positive samples
vascular access placement in the home 1375
